Radioisotope (e.g., Radioimmunoassay, Etc.) Patents (Class 436/804)
-
Patent number: 4604348Abstract: A composition having a protein binding solid support onto which is bound a mixture of antigens and antibodies which are both bound to the solid support individually and are not present in the form of an immune complex.Type: GrantFiled: January 20, 1984Date of Patent: August 5, 1986Assignee: New York Blood Center, Inc.Inventor: A. Robert Neurath
-
Patent number: 4600690Abstract: There is disclosed a method for immunoassay and/or competitive binding assay, wherein an excess amount of unlabeled antigen is added after the start of the reaction between the labeled ligand, the unlabeled ligand, and the binding agent or antibody, to saturate or flood the antibody binding sites. This provides increased sensitivity allowing for more reliable and precise measurements of ligands including antigens than heretofore. The present method extends the scope of applicability of competitive binding technique for assay of hormones, drugs and other compounds.Type: GrantFiled: July 19, 1983Date of Patent: July 15, 1986Assignee: Albert Einstein College of Medicine of Yeshiva University, A division of Yeshiva UniversityInventors: Arthur Karmen, Fred D. Lasky
-
Patent number: 4599305Abstract: A method for detecting chronic myelogenous leukemia in a human comprising the step of testing a biological sample from a patient to determine the presence of a marker protein (P210) which is characterized as a c-abl protein having tyrosine kinase activity and a molecular weight of approximately 210,000. Antisera which are specific for the P210 protein are disclosed which can be used to precipitate the P210 protein to allow identification by gel electrophoresis or other technique.Type: GrantFiled: July 16, 1984Date of Patent: July 8, 1986Assignee: The Regents of the University of CaliforniaInventors: Owen N. Witte, Susan Watanabe, James Konopka
-
Patent number: 4596769Abstract: Several novel hybridoma cell lines, ATCC #HB-8510, 8511, 8512, 8513, 8514, 8515, 8516, and 8517 produce monoclonal antibody to an antigen, peptidoglycan, which is a normal structural component of neREFERENCE TO GOVERNMENTThe invention described herein was supported by National Institutes of Health grants DE-03487 and DE-05160.Type: GrantFiled: March 5, 1984Date of Patent: June 24, 1986Assignee: Temple UniversityInventors: Gerald D. Shockman, Dianne E. Jackson, William Wong
-
Patent number: 4596771Abstract: A continuous hybridoma cell line which secretes recoverable quantities of monoclonal antibodies having specificity against Vitamin B.sub.6, which antibodies are useful in a method for detecting the presence of vitamin B.sub.6 in an animal sample.Type: GrantFiled: May 23, 1984Date of Patent: June 24, 1986Assignee: Research CorporationInventors: John A. Cidlowski, Dace Viceps-Madore
-
Patent number: 4595654Abstract: Method and test kit for detecting Clq-containing complexes in human serum containing native serum Cl. The method uses a monoclonal antibody which selectively reacts with human Clq in the presence of native human serum Cl. Preparation of hybridomas generating such antibodies is also disclosed. The method is applicable to detection of autoimmune diseases and AIDS.Type: GrantFiled: November 7, 1983Date of Patent: June 17, 1986Assignee: Immunomedics Inc.Inventors: Rudolph P. Reckel, Joanne L. Harris, Ralph Wellerson, Jr., Sally M. Shaw, Paul M. Kaplan
-
Patent number: 4595656Abstract: Isocyanate or isothiocyanate substituted lactone or thiolactone is employed for coupling one organic compound to another. For example, such coupling agents can be employed for coupling thyroxine or digoxin to a fluorescent compound for use as a tracer in an assay.Type: GrantFiled: January 6, 1984Date of Patent: June 17, 1986Assignee: Becton Dickinson & CompanyInventors: Stephen D. Allen, Michael Thompson
-
Patent number: 4594319Abstract: This invention is directed to AUT-PK 500, a novel autophosphorylating protein kinase, to the purification and characterization of AUT-PK 500 from rat adrenocortical carcinoma, to the use of AUT-PK 500 as a marker for neoplasia cells, and to a radioimmunoassay for detecting AUT-PK 500 in neoplasia cells.Type: GrantFiled: March 19, 1984Date of Patent: June 10, 1986Assignee: The University of Tennessee Research Corp.Inventor: Rameshwar K. Sharma
-
Patent number: 4591552Abstract: A radiolabeled or enzyme labeled peptide having no more than 60 amino acids in the chain of the peptide; the peptide having covalently linked amino acids disposed in a steric configuration which is recognized by and bound by an antibody. The labeled peptides can be utilized in various processes to detect the presence of a given antibody or antigen in a sample. Hepatitis B surface antigen and antibody to same may be so detected.Type: GrantFiled: September 29, 1982Date of Patent: May 27, 1986Assignee: New York Blood Center, Inc.Inventor: A. Robert Neurath
-
Patent number: 4591573Abstract: A sensitive and specific radioimmunoassay is developed for L-hyoscyamine ulting from atropine administration with which a concentration as low as 25 pg/ml using 0.1 ml of sample can be measured without the need for extraction. Specificity studies indicate that an antibody according to this invention has high specific recognition of L-hyoscyamine with only about 37% cross reaction with the D-hyoscyamine enantiomer of atropine. The antibody is produced from an immunogen having conjugated at least 42 and preferably 45 L-hyoscyamine-p-aminobenzoic acid haptenic molecules per molecule of bovine serum albumin. An antibody according to this invention can be used with a dilution titer as high as 1:2000.Type: GrantFiled: September 23, 1983Date of Patent: May 27, 1986Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Pritam S. Verma
-
Patent number: 4591572Abstract: The present invention concerns an autologous precipitating antibody and the gp70 pigment-associated antigen on melanoma cells which it recognizes. The antibody is useful in detecting pigmented melanoma cells in excised specimen, serum or urine.Type: GrantFiled: April 1, 1983Date of Patent: May 27, 1986Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: M. Jules Mattes, Timothy M. Thomson, Lloyd J. Old, Kenneth O. Lloyd
-
Patent number: 4588698Abstract: Microencapsulation of solid phase scintillators in gels selectively permeable to diffusible radioactive label. These encapsulated scintillators are used to monitor the concentration of radioactive-tagged subtances in fluid systems.Type: GrantFiled: October 19, 1982Date of Patent: May 13, 1986Assignee: University Patents, Inc.Inventors: Sol M. Gruner, Gregory Kirk
-
Patent number: 4588681Abstract: A process for producing an adult T cell leukemia associated antigen is disclosed wherein an adult T cell leukemia associated antigen producing cell is treated with a surfactant. A method for assaying adult T cell leukemia associated antibodies by enzymoimmunoassay, radioimmunoassay or passive hemagglutination is also disclosed. In this method, the adult T cell leukemia associated antigen obtained by treating the adult T cell leukemia associated antigen producing cells with a surfactant is used as the antigen in the assay procedure.Type: GrantFiled: September 23, 1983Date of Patent: May 13, 1986Assignee: Eisai Co., Ltd.Inventors: Takashi Sawada, Tomiaki Morimoto, Isao Miyoshi, Hirokuni Taguchi, Junichi Tohmatsu, Toyohiro Kitamura
-
Patent number: 4587221Abstract: The present invention relates to a method which eliminates centrifugation and decantation steps, to be performed in an automatic manner for carrying out specific binding assay tests, wherein liquid and solid phases are present.According to the invention, use is made of a specially designed device, consisting of a mixing reservoir into which is fitted snugly a mixer separator having a channel in the vertical axis of the mixer-separator. A rack holding a number of said mixing reservoirs containing the incubated reagents and analytes, capped with the mixer separators, is placed into a press-device designed to perform at a controlled rate a downward movement. The mixer separators are pushed downwards into the mixing reservoirs at a chosen rate for a preselected distance to complete the mass transport and separation operations. The separation devices are removed and either one of the separated phases can be measured in the desired analytical instrument for a quantitative or qualitative determination.Type: GrantFiled: December 30, 1983Date of Patent: May 6, 1986Assignee: Technion Research & Development Foundation, Ltd.Inventors: Michael Cais, Moshe Shimoni
-
Patent number: 4585741Abstract: The vitamin D metabolite, calcitriol, is determined in blood serum by radioimmunoassay employing monoclonal antibodies in which calcitroic acid serves as the immunogen.Type: GrantFiled: August 25, 1983Date of Patent: April 29, 1986Inventors: Brian L. Clevinger, John G. Haddad, Steven L. Teitelbaum
-
Patent number: 4585740Abstract: A peptide having the formula ##STR1## is synthesized. The peptide is conjugated, e.g., with bis-diazotized benzidine, at its C-terminus to a carrier, such as bovine serum albumin, to form a synthetic antigen useful for inducing antibody production in a host animal. The antiserum obtained from the host animal is free of cross-reactivity with other pituitary substances and thus particularly advantageous for assay purposes. The peptide, whether unlabeled or labeled with radioactive iodine on the tyrosine moiety, has an affinity to antiserum raised against the conjugate similar to the affinity of natural hPRL to the antiserum. The synthetic peptide is used in radioimmunoassays where the labeled peptide competes for the binding sites in the antiserum with unknown concentrations of hPRL in biological samples.Type: GrantFiled: May 3, 1983Date of Patent: April 29, 1986Assignee: The Whittier Institute for Diabetes and EndocrinologyInventor: Willard P. VanderLaan
-
Patent number: 4584268Abstract: Methods and compositions are provided for detecting the presence of carcinomas in a mammalian host by measuring the level of normal surface antigens specific for a differentiated cell in the serum of the host as compared to the normal level of such antigen. The method finds particular use in detecting residual carcinomas after therapy or in detecting the recurrence of neoplastic tissue, and assigning a tissue of origin to the neoplastic tissue.Type: GrantFiled: February 24, 1984Date of Patent: April 22, 1986Inventors: Roberto L. Ceriani, Jerry A. Peterson
-
Patent number: 4584278Abstract: Methods for the isolation and purification of an antigen, named NB/70K, from human ovarian carcinomas and radioimmunoassays for the detection of ovarian carcinomas, as well as an antibody specific for NB/70K.Type: GrantFiled: January 28, 1983Date of Patent: April 22, 1986Assignee: University of RochesterInventor: Suzanne Knauf
-
Patent number: 4582793Abstract: A method is described for the differential diagnosis of rheumatological diseases. Sera from patients with SLE; MCTD, and RA are screened for antibodies directed against RNA polymerase II using a solid phase immunoassay. Significant levels of the antibodies were detected with sera of all SLE and MCTD patients and in 78% of the RA patients. No detectable anti-RNA polymerase I antibodies were detected in the sera of healthy individuals.Sera from patients with SLE contained immunoglobulins directed against the S3 subunit of RNA polymerase I, as well as antibodies to the S2 or S5 subunits, RA patient's sera contained antibodies only to S3 while MCTD patients sera contained antibody to S4 in addition to antibody to the S3 and S5 subunits. The identification of specific reaction patterns of the antibodies with the individual subunits of the RNA polymerase I is indicative of a particular class of rheumatological disease.Type: GrantFiled: October 29, 1982Date of Patent: April 15, 1986Assignee: Research CorporationInventors: Samson T. Jacob, Kathleen M. Rose, Dean A. Stetler
-
Patent number: 4581222Abstract: An immunoassay method for detection of antigen is disclosed. The method employs complement mediated lysis of vesicles loaded with In-111 or other gamma-emitting cation, and quantitative detection of the lysis by gamma-ray perturbed angular correlation (PAC) spectroscopy. The vesicles are labeled with a substance competitive to the antigen to be measured, and the concentration of the antigen in the sample measured by assessing the diminution in lysis due to the presence of the competing antigen.The method may also be used to assess the immunologic competence of a subject by injecting suitably sensitized vesicles and monitoring the in vivo lysis pattern by (PAC).Type: GrantFiled: February 9, 1983Date of Patent: April 8, 1986Assignee: California Institute of TechnologyInventors: John D. Baldeschwieler, Ronald C. Gamble, Albert M. Lin, George W. Tin
-
Patent number: 4575486Abstract: Urinary particulates in a human subject which have been coated with THP is determined to be from the region of the nephron which is above the Henle loop in the nephron where THP is produced. The identification of those particles in the urine sample which had been coated with THP is performed by subjecting the sample to THP antibodies to form THP antibody-antigen complexes. These complexes can be identified by a number of ways, such as visual, fluorescent, etc. By determining the percentage of the total particulates which have the coating of THP, a diagnostic tool for determining renal disorders is disclosed.Type: GrantFiled: October 26, 1983Date of Patent: March 11, 1986Assignee: International Remote Imaging Systems, Inc.Inventor: Cleve W. Laird
-
Patent number: 4569788Abstract: Monoclonal antibodies 703D4 and 704A1 detect human non-small cell lung cancer (non-SCLC) and distinguish non-SCLC from all other types of lung cancer and normal tissue cells. These two antibodies may be utilized in kit form to distinguish non-SCLC from other forms of lung cancer. These monoclonal antibodies bind to S.sup.35 methionine-incorporating protein doublets under reduced and unreduced conditions. The determinants bound by these antibodies on the 31 kiladalton protein are independent of each other as determined in radiolabelled competition assays.Type: GrantFiled: May 18, 1983Date of Patent: February 11, 1986Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: James L. Mulshine, John D. Minna
-
Patent number: 4568649Abstract: A test kit and assay for detecting the presence of minute amounts of an organic reactant in a test sample includes a plurality of beads or other types of support structures that are impregnated with a fluorescer and coated with a ligand that specifically binds to the organic reactant being investigated. The beads are placed in an aqueous solution, together with the reactant which has been radiolabeled. The portion of the radiolabeled reactant that binds to the ligand is thereby brought in close enough proximity to the beads to activate the fluorescer to produce light energy. The radiolabeled reactant that does not bind to the ligand is, for the most part, disposed too far away from the beads to enable the radioactive energy emitted thereby to reach the fluorescer integrated into the beads. Thus, the level of light energy produced by the fluorescer is indicative of the amount of reactant present in the test sample.Type: GrantFiled: February 22, 1983Date of Patent: February 4, 1986Assignee: Immunex CorporationInventor: Jacques H. Bertoglio-Matte
-
Patent number: 4564597Abstract: Anti-Sm antibodies are produced by the hybridoma technique and employed to test for lupus erythematosus in humans.Type: GrantFiled: March 18, 1981Date of Patent: January 14, 1986Assignee: Research CorporationInventors: Ethan A. Lerner, Michael R. Lerner
-
Patent number: 4563419Abstract: This invention relates to a kit for the detection of microbial nucleic acids and a method for identifying the nucleic acids using a one-step sandwich hybridization technique. The technique requires two complementary nucleic acid reagents for each microbe or group of microbes to be identified.Type: GrantFiled: December 29, 1983Date of Patent: January 7, 1986Assignee: Orion Corporation Ltd.Inventors: Tuula M. Ranki, Hans E. Soderlund
-
Patent number: 4562159Abstract: A method and test kit are disclosed for detecting the presence of hepatitis B virus in a test specimen containing at least a portion of the DNA of the virus. A test reagent comprises cloned hepatitis B virus-DNA that has been repurified by treatment with a restriction enzyme and labelled to high specific activity with a radioactive label. The sample to be tested is fixed to a solid matrix, incubated in the presence of the test reagent under hybridization conditions and detected by hybridization to the labelled DNA probe. The uncombined HBV-DNA (labelled) is removed from the substrate, and the hybridized HBV-DNA determined by scintillation counting or by autoradiography of the substrate.Type: GrantFiled: March 31, 1981Date of Patent: December 31, 1985Assignee: Albert Einstein College of Medicine, A Division of Yeshiva Univ.Inventor: David A. Shafritz
-
Patent number: 4562160Abstract: The present invention concerns novel immunoprecipitating autologous antibodies which recognize the Class 1 gp90 antigen on melanoma cells. These antibodies, optionally tagged with a chromophoric or radioactive label and immobilized on an inert support, may be used to recognize and isolate the gp90 antigen from melanoma cell extracts. Monoclonal antibodies to melanoma may be screened with the gp90 antigen for those which recognize epitopes other than the FD antigenic system.The cell line containing the gp90 antigen which has been cultured in vitro is a source of gp90 antigen for generation of monoclonal antibodies which will be useful in analyzing the gp90 antigen for those epitopes which may be of diagnostic value in immunoassay of melanoma.Type: GrantFiled: April 1, 1983Date of Patent: December 31, 1985Assignee: Sloan-Kettering InstituteInventors: Francisco X. Real, M. Jules Mattes, Alan N. Houghton, Philip O. Livingston, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4558013Abstract: Method and apparatus for use in accurately measuring the binding reactions occurring between a predetermined class of components in a liquid specimen and their corresponding binding conjugates coated on separate test regions of a carrier. The carrier further includes a reference region that is uncoated, and the carrier is adapted for simultaneous contact of all of its regions with the liquid specimen. Any resulting binding reaction on each test region indicates both specific binding to the coated component as well as non-specific binding, and any resulting binding reaction on the reference region indicates merely non-specific binding. The measurements for the test regions are all reduced by an amount determined in accordance with the measurement for the reference region, to reduce the effects of non-specific binding on those measurements and thereby provide accurate measurements of the specific binding on each coated component.Type: GrantFiled: April 8, 1983Date of Patent: December 10, 1985Assignee: Mast Immunosystems, Ltd.Inventors: Vincent A. Marinkovich, David H. Riege, John W. Dyminski
-
Patent number: 4554256Abstract: Early pregnancy can be determined by detection of a protein in serum, which protein is associated with the placental membrane. The protein is characterized by having an approximate molecular weight of 47,000 to 53,000 and an isoelectric point of from about 4.0-4.4.Type: GrantFiled: July 21, 1983Date of Patent: November 19, 1985Assignee: The Idaho Research Foundation, Inc.Inventors: R. Garth Sasser, William C. Hamilton
-
Patent number: 4551426Abstract: A heterogeneous immunoassay for digoxin. An excess of labeled anti-digoxin antibody is added to a test sample and the resulting reaction mixture is contacted with a solid phase having ouabain immobilized thereon. All the free, labeled antibody binds to the oubain. The eluted digoxin anti-digoxin antibody complex is measured for label activity. A competitive mode is also disclosed.Type: GrantFiled: January 18, 1984Date of Patent: November 5, 1985Assignee: E. I. Du Pont de Nemours and CompanyInventors: William J. Freytag, Shung-Ho Chang
-
Patent number: 4550085Abstract: Histamine is detected or determined selectively in a sample by causing the sample to contact glass microfibers in such a quantitative proportion as will permit the histamine present to bind to the fibers. The amount of bound histamine may be determined by competitive determination in the presence of labelled histamine on the basis of a standard curve, or may be determined directly by conventional coupling reactions.The method is simple and particularly useful for allergy diagnostics because it exhibits good correlation with known fluorometric methods.Type: GrantFiled: September 8, 1981Date of Patent: October 29, 1985Inventors: Per S. Skov, Svend Norn, Bent Weeke
-
Patent number: 4550086Abstract: A monoclonal antibody which specifically binds to the surface recognition structure of a predetermined mature human T cell clone, which recognition structure renders the clone capable of acting as causative agent in a predetermined autoimmune disease, the monoclonal antibody being capable of specifically binding to the recognition structure of the clone to inhibit the ability of the clone to act as a causative agent in the predetermined autoimmune disease.Type: GrantFiled: February 16, 1983Date of Patent: October 29, 1985Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Ellis L. Reinherz, Stuart F. Schlossman, Stefan C. Meuer
-
Patent number: 4548909Abstract: A method of diagnosis using an attached material for binding to an immune complex, by treating the bound complex with a series of different reagents or mixtures thereof and detecting the presence or absence of reaction in each case, this method being based on immune complexes produced in the body during infection and allowing much earlier detection and diagnosis of infection thereby providing the facility for treatment to reduce the damage caused to the body by the formation of complex.Type: GrantFiled: June 11, 1982Date of Patent: October 22, 1985Inventor: David Parratt
-
Patent number: 4543340Abstract: A radioimmunoassay for the polypeptide thymic hormone thymosin .beta..sub.4 is described. The assay employs a radiolabelled Tyr-C13-thymosin .beta..sub.4 -analogue as probe and a thymosin .beta..sub.4 antibody.Type: GrantFiled: April 7, 1983Date of Patent: September 24, 1985Assignee: George Washington UniversityInventors: Allan L. Goldstein, Teresa L. K. Low, John McClure, Paul H. Naylor
-
Patent number: 4543439Abstract: A hybridoma cell line is disclosed that secretes monoclonal antibodies which serve as a high titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins. In addition, the antibodies have potential uses in diagnosis of a variety of diseases, including certain cancers. The antibodies, which have demonstrated affinity for a variety of molecules containing o-phosphotyrosine residues, were prepared using a synthetic analog, p-azobenzyl phosphonate (ABP) covalently linked to a carrier protein, as the antigen.Type: GrantFiled: December 13, 1982Date of Patent: September 24, 1985Assignee: Massachusetts Institute of TechnologyInventors: A. Raymond Frackelton, Jr., Herman N. Eisen, Alonzo H. Ross
-
Patent number: 4532220Abstract: There is provided an assay for the determination of the carcinogenicity of chemical and physical agents, by exposing a selected line of tumor virus transformed cells to the agent to be tested and determining whether such exposure induces endogenous viral DNA replication in such cells, which induction is indicative of the carcinogenicity of the tested agent by in situ hybridization. There is provided a kit for carrying out such assay.Type: GrantFiled: March 23, 1982Date of Patent: July 30, 1985Assignee: Yeda Research and Development Company Ltd.Inventor: Sara Lavi
-
Patent number: 4530908Abstract: Antibodies and antigens are disclosed which provide a method of detecting and a method of combating flukes. A diagnostic method for the determination of an active fluke infection in a warm-blooded animal is provided which comprises the testing of body serum or body fluids for the presence of fluke spine glycoprotein or anti-spine antibodies. Fused cell hybrids ATCC HB-8086, ATCC HB-8087 and ATCC HB-8088, as well as the antibodies produced by the fused cell hybrids, are also provided.Type: GrantFiled: April 27, 1983Date of Patent: July 23, 1985Assignee: The Johns Hopkins UniversityInventor: Mette Strand
-
Patent number: 4529713Abstract: Novel radioactive stilbene derivatives marked with iodine 125 or 131 of the formula ##STR1## wherein each A and B are both hydrogen or together form a double bond and R is the remainder of amino acid of the formula R--NH.sub.2 or a derivative thereof possessing an iodine acceptor group and marked with iodine 125 or 131 and their preparation and antigens obtained therefrom and a process for preparing said antigens.Type: GrantFiled: June 22, 1982Date of Patent: July 16, 1985Assignee: Roussel UclafInventors: Alain Jouquey, Gaetan Touyer
-
Patent number: 4528131Abstract: A process for preparing a stable receptor preparation suitable for the quantitative determination of substances able to bind to cerebral receptors in which a brain or brain-region material is homogenized with an aqueous solution of an inert substance soluble in water; the formed homogenizate is centrifuged at an acceleration of 800 to 110 g for 8 to 20 minutes to form a supernatant; the brain or brain-region material is isolated from the supernatant by centrifuging the supernatant at an acceleration of 18,000 to 22,000 g for 10 to 20 minutes, the thus-obtained solid substance is rehomogenized in distilled water; the homogenizate is frozen and then thawed and thereafter centrifuged at an acceleration of 7000 to 9000 g for 5-15 minutes; the supernatant is isolated, centrifuged at an acceleration of 35,000 to 45,000 g for 20 to 30 minutes; the obtained solid substance is washed with an aqueous buffer solution of a pH value between 6 and 8, and a suspension consisting of the solid substance and the washing liquidType: GrantFiled: February 28, 1983Date of Patent: July 9, 1985Assignee: MTA Kozponti Kemiai Kutato IntezetInventors: Julianna Kardos, Gabor Maksay, Miklos Simonyi
-
Patent number: 4528134Abstract: Method of separating A.sub.14 -.sup.125 I-insulin from heterogeneously labeled insulin molecules for biological studies which involves iodating insulin in a controlled manner, selectively absorbing the insulin from the iodination procedure in a tightly packed bed of octadecylsilane bonded to silica employing reverse phase liquid chromatography principles, thereafter eluting large and small radioactive and nonradioactive materials such as damaged insulin, various contaminants and polar materials from the bed with dilute trifluoroacetic acid, thereafter eluting the intact .sup.125 I-insulin from the bed with a mixture of acetonitrile and dilute trifluoroacetic acid and then separating the A.sub.14 -insulin by high performance liquid chromatography or ion exchange chromatography.Type: GrantFiled: December 27, 1982Date of Patent: July 9, 1985Assignee: University of TN Research CorporationInventors: Frankie B. Stentz, Reba K. Wright, Abbas E. Kitabchi
-
Patent number: 4526871Abstract: The present invention relates to a conjugate of a specific ligand and a lectin, by covalent bonding.The product of the invention may, for example, be the conjugate of Concanavalin A and an antigen, a hapten, an antibody, a hormone or its receptor, an enzyme or its inhibitor or a lectin. Coupling being effected by means of glutaraldehyde or p-benzoquinone.Type: GrantFiled: May 20, 1981Date of Patent: July 2, 1985Assignee: Institut PasteurInventors: Stratis Avrameas, Jean-Luc Guesdon
-
Patent number: 4525459Abstract: Preparations useful in the diagnosis of infectious mononucleosis are disclosed. Horse and sheep erythrocytes are purified and essentially homogenous glycoproteins are extracted. The purified glycoproteins are useful as antigens in testing for the presence of the heterophile antibodies of infectious mononucleosis and in the preparation of reagents for the enumeration of rosetting lymphocytes without having to have available fresh sheep blood.Type: GrantFiled: January 27, 1982Date of Patent: June 25, 1985Assignee: University of MiamiInventor: Mary A. Fletcher
-
Patent number: 4522922Abstract: Ligand having at least two determinant or binding sites is contacted with a labeled first binder, an unlabeled second binder different than the first binder and a precipitating binder specific for the second binder, with such contacting precipitating a complex of the ligand and the first and second binders to thereby separate bound labeled binder from unbound labeled binder. The bound and/or unbound labeled binder is determined as a measure of the ligand.Type: GrantFiled: April 16, 1982Date of Patent: June 11, 1985Inventors: Jose Carro, Frank de Velasco
-
Patent number: 4520112Abstract: A method for measuring the level of organic calcium antagonist drug in a body fluid comprises preparing a mixture of a radioactive calcium antagonist drug, a body fluid containing a calcium antagonist drug and a calcium antagonist receptor material, measuring the radioactivity of the radioactive calcium antagonist drug bound to said calcium antagonist receptor material and deriving the concentration of the calcium antagonist drug in the body fluid from a standard curve indicating the concentration of calcium antagonist drug versus inhibition of binding of said radioactive calcium antagonist drug to said receptor sites caused by the calcium antagonist drug in said body fluid. A kit for measuring the level of an organic calcium drug comprises a receptacle containing a radioactive calcium antagonist drug, a calcium antagonist receptor material and a standard amount of a nonradioactive calcium antagonist drug.Type: GrantFiled: March 9, 1983Date of Patent: May 28, 1985Assignee: The Johns Hopkins UniversityInventors: Solomon H. Snyder, Robert J. Gould
-
Patent number: 4520113Abstract: This invention relates to the detection of antibodies in sera of AIDS and pre-AIDS patients and describes the biochemical and immunological analysis of antigens associated with the virus HTLV-III Human T-Cell Leukemia Virus. It is shown that antigens associated with the infection of human cells by this virus are specifically recognized by antibodies from AIDS patients. Specifically, HTLV-III isolated from AIDS patients and transmitted by cocultivation with an HT cell line is specifically detected by antibodies from human sera taken from AIDS patients. The method of detection of antibodies preferred is a strip radioimmunoassay (RIA) based on the Western Blot technique or an ELISA (an enzyme-linked immunosorbent assay) or an indirect immunofluorescence assay.Type: GrantFiled: April 23, 1984Date of Patent: May 28, 1985Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 4514509Abstract: A rapid, sensitive, and specific method for diagnosing Legionnaires' disease through the detection of antigens excreted by the patient and a method for preparing anti-Legionella immunoglobulin G for use in such diagnostic method.Type: GrantFiled: September 21, 1981Date of Patent: April 30, 1985Assignee: Indiana University FoundationInventors: Richard B. Kohler, Arthur C. White
-
Patent number: 4514506Abstract: The invention comprises a method for the purification of a human lung tumor-associated antigen (hLTAA) specific to human lung tumors of diverse histological characteristics; serum levels of hLTAA correlate with lung tumor incidence, and appear to usefully discriminate between various stages of the malignancies. The invention further comprises an immunoassay predicated on purified hLTAA for the detection and quantitative determination of hLTAA in biological fluids, particularly blood serum, and diagnostic systems for clinical immunoassay procedures.Type: GrantFiled: January 28, 1983Date of Patent: April 30, 1985Assignee: The Government of the United States as represented by the Secretary of the Department of Health and Human ServicesInventors: James A. Braatz, Kenneth R. McIntire, Gerald L. Princler
-
Patent number: 4514505Abstract: Mixtures of monoclonal antibodies which contain effective assaying amounts of each of at least two monoclonal antibodies that bind to different antigenic sites on the antigen and are capable under appropriate conditions of binding simultaneously to an antigen are useful in enhanced sensitivity assays for the antigen. By utilizing such mixtures in diagnostic assays for important antigens such as the polypeptide human chorionic gonadotropin enhanced sensitivity can be achieved as compared with assays employing individual monoclonal antibodies.Type: GrantFiled: May 21, 1982Date of Patent: April 30, 1985Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Paul H. Ehrlich, William R. Moyle
-
Patent number: 4513088Abstract: An assay that facilitates screening of hybridoma culture media for monoclonal anti-idiotype antibodies, particularly murine monoclonal antibodies that are useful for treating human B cell tumors is disclosed. The assay is a solid phase type assay and involves: incubating a lysate of the patienREFERENCE TO GOVERNMENT GRANT OR CONTRACTThe invention described herein was made in the course of work under a grant or contract from the National Institutes of Health.Type: GrantFiled: March 30, 1983Date of Patent: April 23, 1985Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ronald Levy, David G. Maloney, Kristiaan Thielemans
-
Patent number: RE32098Abstract: This invention relates to a highly accurate, rapid and simple estimation of thyroxine (T.sub.4) directly from blood serum and also relates to the accurate measurement of triiodo-L-thyronine (T.sub.3) directly from blood serum. More specifically, the invention relates to a rapid, specific and reliable radioimmunoassay (RIA) technique for measurement of both T.sub.4 and T.sub.3 in unextracted serum. The method requires very small amounts of serum, e.g., 25 microliters (.mu.l) to measure T.sub.4 concentration in nearly all specimens representing clinical states of eu-, hypo- and hyperthyroidism, and 250 .mu.l to measure T.sub.3 concentrations in specimens representing most clinical states.Type: GrantFiled: August 10, 1978Date of Patent: March 25, 1986Assignee: Research and Education Institute, Inc.Inventor: Inder J. Chopra